2-(dimethylamino)-2,5-dimethylhexan-3-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(dimethylamino)-2,5-dimethylhexan-3-one
• 英文别名: 4-(Dimethylamino)-2,5-dimethylhexan-3-one；4-(dimethylamino)-2,5-dimethylhexan-3-one
• 化学式: C₁₀H₂₁NO
• 分子量: 171.283
• InChiKey: ADTKZJJFMIVBMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N,N,2-三甲基丙酰胺 在 dimethyl(phenyl)silyl lithium 、 盐酸 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 生成 2-(dimethylamino)-2,5-dimethylhexan-3-one
  参考文献：
  名称：

  苯基二甲基甲硅烷基锂与N，N-二取代酰胺的非凡反应。

  摘要：

  苯基二甲基甲硅烷基锂以各种方式与N，N-二甲基酰胺反应，具体取决于化学计量，温度以及最巧妙地取决于酰胺的结构，结构中似乎很小的变化导致其性质的深刻变化。产品。当将等摩尔量的甲硅烷基锂试剂和N，N-二甲基酰胺6在-78℃下在THF中混合，并将混合物在-78℃下淬灭时，产物是相应的酰基硅烷。如果在淬灭之前将同一混合物加热至-20摄氏度，则该产品为顺式二烯胺11。二烯胺容易从顺式异构化为反式，易氧化为二烯二胺，更难水解为α-氨基酮13。如果使用两当量的甲硅烷基锂试剂，则产物为α-甲硅烷基胺20。烯二胺的形成机理似乎是通过四面体中间体17的布鲁克重排，随后是硅烷氧化物的损失，从而得到卡宾或卡宾类物质。“卡宾”与布鲁克重排亲核试剂结合，得到中间体28，该中间体失去另一个硅烷氧化物离子，得到烯二胺。相同的卡宾可被第二当量的甲硅烷基锂试剂攻击，得到α-甲硅烷基胺20。其他亲核试剂，如烷基锂，苯基锂和三丁

  DOI：

  10.1039/b412768d

文献信息

• The reductive coupling of tertiary amides to give enediamines using PhMe2SiLi
  作者：Ian Fleming、Usha Ghosh、Stephen R. Mack、Ian Fleming、Usha Ghosh、Stephen R. Mack、Barry P. Clark

  DOI：10.1039/a800648b

  日期：——

  PhMe2SiLi reacts with tertiary amides to give enediamines, which can be isolated in good yield when the α-carbon is branched; the enediamines can be hydrolysed more or less easily to α-amino ketones, isomerised from Z to E, oxidised to dienediamines and isomerised to amino enamines.

  PhMe2SiLi 与三级酰胺反应生成烯二胺，当α-carbon为支链时可以以良好的产率分离；烯二胺可以或多或少容易地水解为α-氨基酮，异构化为E型，氧化为二烯二胺，并异构化为氨基烯胺。
• FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES
  申请人：Rosenblum Stuart B.

  公开号：US20120251491A1

  公开（公告）日：2012-10-04

  The present invention relates to novel Fused Tricyclic Aryl Compounds, compositions comprising at least one Fused Tricyclic Aryl Compound, and methods of using the Fused Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient.
• ANTIVIRAL COMPOUNDS OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C
  申请人：Zeng Qingbei

  公开号：US20120258078A1

  公开（公告）日：2012-10-11

  The present invention relates to novel Linked Tricyclic Aryl Compounds, compositions comprising at least one Linked Tricyclic Compound, and methods of using Linked Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient. in one aspect, the present invention provides Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein: Non-limiting examples of the Compounds of Formula (II) include compound 56
• FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS
  申请人：Chen Kevin X.

  公开号：US20130156731A1

  公开（公告）日：2013-06-20

  The present invention relates to novel Fused Tricyclic Compounds, compositions comprising at least one Fused Tricyclic Compound, and methods of using Fused Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient.
• Antiviral Compounds Composed of Three Aligned Aryl Moieties to Treat Diseases such as Hepatitis C
  申请人：Chen Kevin X.

  公开号：US20130164258A1

  公开（公告）日：2013-06-27

  The present invention relates to novel Tricyclic Compounds, compositions comprising at least one Tricyclic Compound, and methods of using Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient. The present invention provides Tricyclic Compounds of Formula (I): Non-limiting examples of the Compounds of Formula (I) include compound 44 The Compounds of Formula (II) can be useful for inhibiting HCV viral replication or replicon activity, and for treating or pre-venting HCV infection in a patient.